Surgery for the Prevention and Treatment of Lymphedema

Coverage Summary

This UnitedHealthcare medical policy addresses surgical procedures proposed for the prevention or treatment of lymphedema for UnitedHealthcare Commercial and Individual Exchange benefit plans. It summarizes coverage rationale, definitions, evidence review, and applicable procedure codes and states the policy position that these surgical procedures are unproven and not medically necessary due to insufficient evidence of safety and/or efficacy. The policy is effective January 1, 2026.

Note: inclusion of procedures or procedure codes in the policy does not imply coverage. Benefit coverage is determined by the member-specific benefit plan document and applicable laws; in the event of conflict, the member-specific plan governs.

Medical Necessity Determinations

Not Medically Necessary

Surgical procedures for the prevention or treatment of Lymphedema are unproven and not medically necessary due to insufficient evidence of safety and/or efficacy.

Procedures included (but not limited to): Axillary Reverse Mapping (ARM), Liposuction/Lipectomy, Microsurgical treatment (e.g., Lymphaticovenous Anastomosis, Lymphaticovenous bypass), Vascularized Lymph Node Transfer.

Evidence synthesis and applicability

ILR/LYMPHA during ALND: Immediate lymphatic reconstruction (ILR)/LYMPHA during axillary lymph node dissection (ALND) for breast cancer

Multiple meta-analyses and RCTs show reduced incidence of breast cancer-related lymphedema (BCRL) with ILR/LYMPHA versus ALND alone; evidence limited by small samples, short follow-up, and heterogeneity.

LVA: Lymphaticovenous anastomosis (LVA) for prevention or treatment

Systematic reviews and Cochrane report reduced incidence or severity in some studies but overall low certainty and lack of high-quality RCTs.

VLNT: Vascularized lymph node transfer (VLNT) for treatment of existing lymphedema

Some evidence (GRADE 1B per AAPS) supports effectiveness in reducing severity; evidence quality variable.

Liposuction (specialized lymphatic liposuction) for chronic non-pitting lymphedema

Applicable Procedure Codes (reference)

Applicable CPT / HCPCS procedure codes (reference only)mixed

1019T	Lymphovenous bypass, including robotic assistance, when performed, per extremity.
15830	Excision, excessive skin and subcutaneous tissue (includes lipectomy); abdomen, infraumbilical panniculectomy.
15832	Excision, excessive skin and subcutaneous tissue (includes lipectomy); thigh.
15833	Excision, excessive skin and subcutaneous tissue (includes lipectomy); leg.
15834	Excision, excessive skin and subcutaneous tissue (includes lipectomy); hip.
15835	Excision, excessive skin and subcutaneous tissue (includes lipectomy); buttock.
15836	Excision, excessive skin and subcutaneous tissue (includes lipectomy); arm.
15837	Excision, excessive skin and subcutaneous tissue (includes lipectomy); forearm or hand.
15838	Excision, excessive skin and subcutaneous tissue (includes lipectomy); submental fat pad.
15839	Excision, excessive skin and subcutaneous tissue (includes lipectomy); other area.

1–10 of 17

1/2

Applicable CPT (updated list referenced)CPT

1019T

Added to applicable CPT codes (specific descriptor not provided in this part)

Provider Actions & Billing Guidance

Documentation Required

Benefit and evidence considerations

Benefit and evidence considerations: Providers should note that the list of procedure codes is provided for reference only. Listing of the codes does not imply coverage; benefit coverage is determined by the member-specific benefit plan document and applicable laws.

Affected codes: 1019T, 15830, 15832, 15833, 15834, 15835, 15836, 15837, 15838, 15839, 15847, 15876, 15877, 15878, 15879, 38999, 49906
Listing of codes is for reference only and does not imply coverage

Documentation Required

Reference member-specific benefits and mandates

Reference member-specific benefits and mandates: Before applying this policy, verify the member-specific benefit plan document and any applicable federal or state mandates, as the member document governs in the event of conflict.

Background, Evidence Summary & Definitions

Lymphedema is a chronic progressive condition whose first-line treatment is conservative management with complete decongestive therapy (CDT) — including compression garments, manual lymphatic drainage, skin care, exercise, and adjunctive pneumatic compression as needed. For individuals who do not respond adequately to CDT, a range of surgical interventions (for example, Axillary Reverse Mapping, lymphaticovenous anastomosis/bypass, vascularized lymph node transfer, liposuction/lipectomy, and excisional/debulking procedures) have been proposed but remain investigational.

The available literature is heterogeneous, with inconsistent outcome measures and variable patient selection; many surgical studies are observational, have small cohorts, and have limited long-term follow-up. Because of these limitations, surgical interventions for lymphedema lack sufficient high-quality evidence to establish durable safety and efficacy across patient populations.

Evidence item	Value/Result
ARM pooled rate (Co 2022)
ARM 4.8% vs AD 18.8%
Hahn 2025 pooled clinical improvement (all microsurgical)
36.46% (95% CI: 29.44-43.48)
Meuli 2023 overall excess volume reduction
≈32.7%
Hinson 2025 immediate LVA prevention meta-analysis
69% lower risk of secondary lymphedema (1722 LVA vs 1975 control)
Randomized controlled trial (Coriddi et al.)
Preliminary RCT showed ILR reduced cumulative BCRL incidence (ILR 2.0%, 9.5%, 9.5% vs control 18%, 24%, 32% at 12, 18, 24 months respectively)
Cochrane
Low certainty evidence supporting LVA reducing incidence; not enough high-quality evidence for widespread adoption
Meta-analysis cohort sizes
Example: 3697 individuals; 1722 immediate LVA vs 1975 controls with 69% lower risk reported

Evidence synthesis shows a low-to-moderate quality body of literature with substantial heterogeneity across studies. Systematic reviews, meta-analyses, and some randomized and comparative studies report benefit in select settings (for example, reduced incidence of breast cancer–related lymphedema with immediate lymphatic reconstruction/LYMPHA or LVA in some analyses, and volume or symptom reduction after VLNT or liposuction in selected patients).

However, many studies are observational or small randomized trials with short follow-up, inconsistent outcome measures, and variable techniques, limiting generalizability. Overall, the evidence is insufficient to support broad coverage of surgical procedures for prevention or treatment of lymphedema.

Term	Definition
Axillary Reverse Mapping (ARM)
A technique that injects blue dye in the upper extremity to allow visualization and preservation of lymphatic channels and lymph nodes during axillary lymph node dissection.
Liposuction/Lipectomy
A procedure that uses vacuum suction to remove subcutaneous adipose tissue in certain anatomical areas.
Lymphaticovenular/Lymphaticovenous Anastomosis (LVA)
Surgical procedure that connects small lymphatic vessels to adjacent venules to shunt excess lymphatic fluid.
Lymphedema
Build-up of fluid in soft body tissues when the lymph system is damaged or blocked.
Vascularized Lymph Node Transfer (VLNT)
Surgical procedure that transfers skin, fat, and lymph nodes for lymphatic reconstruction.
Immediate lymphatic reconstruction (ILR)/LYMPHA
Microsurgical procedures performed at time of lymph node dissection to reconnect lymphatics to venous circulation to prevent secondary lymphedema.
Debulking/liposuction
Surgical removal of fat and fibrotic tissue for chronic non-pitting lymphedema; requires lifelong compression.

Revision History

01/01/2026template_update

Template update and archived previous policy version 2025T0636G; created shared policy version to support application to Oxford plan membership and updated applicable CPT codes (added 1019T).